Response to Editor: Breast Cancer Risk in Primary Ovarian Insufficiency
Overview
This letter critiques a recent study claiming increased breast cancer risk in all women with primary ovarian insufficiency (POI). It highlights potential biases in the study design and emphasizes that elevated risk may apply only to a subset of women with specific genetic factors.
Background
Primary ovarian insufficiency (POI) affects approximately 1% of women under 40 and is commonly treated with physiologic hormone replacement therapy (HRT). Prior research has suggested that earlier menopause, including POI, may be associated with lower breast cancer risk. The recent study by Allen-Brady et al asserted a broad increased breast cancer risk in all women with POI, a claim that warrants careful scrutiny given the clinical implications of HRT prescribing.
Data Highlights
The study identified 613 women with POI from the Utah Population Database of over 3.5 million health records, a number lower than expected given the estimated 1% prevalence of POI. For comparison, another study found 3971 spontaneous POI cases in a population of 5.5 million. This discrepancy suggests potential under-ascertainment and selection bias in the cohort.
Key Findings
The broad claim that all women with POI have increased breast cancer risk is likely overstated.
The retrospective study design using electronic medical records is prone to cohort selection bias and missing data.
Underdiagnosis and undercoding of POI likely led to underrepresentation of otherwise healthy women with POI in the study cohort.
Women with breast cancer may have had more healthcare encounters, increasing their likelihood of being included.
Genetic factors related to DNA repair may increase breast cancer risk in a subset of women with POI, but this does not apply universally.
Physiologic HRT remains important for symptom relief and prevention of osteoporosis and cardiovascular disease in women with POI.
Clinical Implications
Clinicians should interpret the reported association between POI and breast cancer risk with caution and avoid generalizing increased risk to all women with POI. Maintaining appropriate HRT use in POI is critical to prevent serious morbidity. Further research is needed to identify which subsets of women with POI may have elevated breast cancer risk due to genetic factors.
Conclusion
The evidence does not support a universal increased breast cancer risk in all women with POI. Careful patient evaluation and individualized risk assessment remain essential, and HRT should not be withheld based on overstated cancer risk claims.
References
Allen-Brady et al 2023 -- The Association Between Primary Ovarian Insufficiency and Elevated Breast Cancer Risk in Women
Savukoski et al 2021 -- Prevalence of Spontaneous Primary Ovarian Insufficiency
Women's Health Initiative Study 2002 -- Hormone Replacement Therapy and Breast Cancer Risk
